Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer.

Tőkés AM, Rusz O, Cserni G, Tóth E, Rubovszky G, Tőkés T, Vízkeleti L, Reiniger L, Kószó R, Kahán Z, Kulka J, Donia M, Vörös A, Szallasi Z.

Acta Oncol. 2019 Jul 4:1-9. doi: 10.1080/0284186X.2019.1633015. [Epub ahead of print]


Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series.

Rusz O, Kószó R, Dobi Á, Csenki M, Valicsek E, Nikolényi A, Uhercsák G, Cserháti A, Kahán Z.

Onco Targets Ther. 2018 Sep 4;11:5459-5463. doi: 10.2147/OTT.S170736. eCollection 2018.


Prone Positioning on a Belly Board Decreases Rectal and Bowel Doses in Pelvic Intensity-Modulated Radiation Therapy (IMRT) for Prostate Cancer.

Kószó R, Varga L, Fodor E, Kahán Z, Cserháti A, Hideghéty K, Együd Z, Szabó C, Borzási E, Szabó D, Müllner K, Varga Z, Maráz A.

Pathol Oncol Res. 2019 Jul;25(3):995-1002. doi: 10.1007/s12253-018-0436-2. Epub 2018 Jun 7.


Daily Setup Accuracy, Side-effects and Quality of Life During and After Prone Positioned Prostate Radiotherapy.

Varga L, Kószó RL, Fodor E, Cserháti A, Varga Z, Darázs B, Kahán Z, Hideghéty K, Borzási E, Szabó D, Müllner K, Maráz A.

Anticancer Res. 2018 Jun;38(6):3699-3705. doi: 10.21873/anticanres.12648.


Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma.

Maráz A, Cserháti A, Uhercsák G, Szilágyi É, Varga Z, Révész J, Kószó R, Varga L, Kahán Z.

BMC Cancer. 2018 Mar 15;18(1):296. doi: 10.1186/s12885-018-4209-9.


A simple clinical method for predicting the benefit of prone vs. supine positioning in reducing heart exposure during left breast radiotherapy.

Kahán Z, Rárosi F, Gaál S, Cserháti A, Boda K, Darázs B, Kószó R, Lakosi F, Gulybán Á, Coucke PA, Varga Z.

Radiother Oncol. 2018 Mar;126(3):487-492. doi: 10.1016/j.radonc.2017.12.021. Epub 2018 Jan 17.


Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study.

Kószó R, Sántha D, Büdi L, Erfán J, Győrfy K, Horváth Z, Kocsis J, Landherr L, Hitre E, Máhr K, Pajkos G, Pápai Z, Kahán Z.

Pathol Oncol Res. 2017 Jul;23(3):505-511. doi: 10.1007/s12253-016-0129-7. Epub 2016 Oct 22.


Cardiac Surveillance Findings During Adjuvant and Palliative Trastuzumab Therapy in Patients with Breast Cancer.

Valicsek E, Kószó R, Dobi Á, Uhercsák G, Varga Z, Vass A, Jebelovszky É, Kahán Z.

Anticancer Res. 2015 Sep;35(9):4967-73.


Supplemental Content

Support Center